CliffBio
biologic

Elzonris

tagraxofusp-erzs

Loss of exclusivityDecember 2030projected — 12-year biologic exclusivity estimate
CompanyStemline Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameElzonris
Active ingredienttagraxofusp-erzs
Strength1,000MCG/1ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2018
Marketing statusRx

More from Stemline Therapeutics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found